Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Patent No. 12,245,962 titled “Balloon Sealing and Fill Valve”. These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the treatment of obesity that includes an enhanced valve for Balloon filling and an innovative mechanism that controls balloon opening. These patents are expected to provide protection through April 2043. With the issuance of these patents, the Company now has 22 patents issued in the U.S. and 64 patents issued globally.
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss with the Allurion Virtual Care Suite, including the Allurion Mobile App and Connected Scale for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform. Patients on the Allurion Program lose 10-15% of their total body weight and in certain studies have been shown to increase their muscle mass.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.